This site is intended only for healthcare professionals residing in Singapore
Menu
Close
Menu
Close
Bacterial resistance to existing antibiotics is an evolving global crisis. Gram-positive bacteria
include some of the most widespread resistant pathogens, which form serious clinical
challenges.1 Prompt identification of such bacteria can help to enable early, appropriate
therapy and stop the spread of infection.2
PREDICTING THE POSITIVE
In WHO's (World Health Organization) list of bacterial priority pathogens, certain multi-drug
resistant Gram-positive bacteria were highlighted as being of particular concern.
These bacteria are responsible for serious healthcare- and community-associated infections, such as pneumonia and bacteremia:1,3
• Methicillin-resistant Staphylococcus aureus (MRSA) infections are common in both hospital and community settings.4
• Vancomycin-resistant Enterococcus faecium (VRE) is a major nosocomial pathogen worldwide, with infections typically presenting in immunosuppressed patients.5
• β-lactamase-resistant Staphylococcus pneumoniae infections are a serious threat to global health.6
Read about ways to detect these infections below:4,6,8
MRSA infections4 |
VRE infections6 | β-lactamase-resistant Staphylococcus pneumoniae infections8 |
---|---|---|
PHENOTYPIC |
STANDARD | STANDARD |
• Oxacillin and cefoxitin disc diffusion test • Oxacillin agar screening test • Determination of minimum inhibitory concentration for oxacillin and cefoxitin |
• Culture – broth or agar, disk diffusion, and E-test • Immunoassay – e.g. ELISA and lateral flow • Molecular methods – includes multiplex PCR |
• Culture methods |
MOLECULAR | NOVEL | NOVEL |
• Detection of the mecA gene – usually the preferred method due to its high sensitivity and specificity | • Electrochemical DNA biosensors – assists ELISA and PCR in identifying and quantifying bacteria |
• Nucleic acid amplification • Antigen detection • Immunochromatographic testing • PCR methods |
DIAGNOSE WITHOUT DELAY
When treating infections caused by Gram-positive bacteria, there’s no time to wait. Getting the treatment right the first time is critical.9–12
For patients with community-acquired pneumonia, initial treatment failure can lead to 3x higher mortality.9–12 So, when concerns for infections arise, treatment is often initiated empirically – without confirmatory culture results.13
However, inappropriate antibiotic regimens can lead to the development of resistance.2,13
Using diagnostic tools to obtain an accurate antibiotic – promptly – can guide therapy and
improve patient outcomes.2
Data-driven predictions of bacterial infection risk based on patient features could help improve patient outcomes, inform clinical decisions, shorten the duration of unnecessary empiric antibiotic therapy, and enhance antibiotic stewardship efforts.13 For example, predictive modelling could identify patients at low risk for MRSA, thus eliminating their potential exposure to unnecessary anti-MRSA therapy.14
PICK OUT THE PATIENT
Who is your Gram-positive patient?
Quid ex eo est consecutus? laudem et benivole collegisti, nec segniorem ad modum, quaeso, interpretaris? sicine eos et dolorem ipsum per se ipsam voluptatem, quia consequuntur magni dolores eos, qui dolorem ipsum, quia dolor sit, amet, consectetur, adipisci velit.
What do global bodies say about the management of bacterial infections?
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
Copyright © 2024 Pfizer Limited. All rights reserved.